Your Health, We Care
Another NameBraftovi,LuciEncor,康奈非尼
IndicationsIt is indicated for the treatment of unresectable or metastatic melanoma, colorectal cancer and non-small cell lung cancer with BRAF V600E or V600K mutations.
Reg No.08 L 1184/24
Inspection NO.2011-24
Encorafenib is a prescription drug approved for marketing by the U.S. Food and Drug Administration (FDA) in 2018. It is indicated for BRAF V600E and BRAF V600K gene mutations confirmed by an FDA-approved test, and must be used strictly in accordance with medical advice.
BRAF V600E and BRAF V600K gene mutations (confirmation via an FDA-approved test is required).
Encorafenib can inhibit the proliferation of tumor cell lines expressing BRAF V600E, V600D and V600K mutations in vitro.
Route and frequency of administration for Encorafenib: Oral administration, once daily.
The dosage of Encorafenib needs to be adjusted according to the patient's actual condition; for specific details, patients should consult their physicians and follow medical advice strictly.
Recommended reading: Dosage and Administration of Encorafenib
Common adverse reactions: Dizziness, syncope.
Serious adverse reactions: Risk of new primary skin cancer, cardiac disorders, hepatic disorders, myopathy, etc.
Reference article: Adverse Reactions of Encorafenib
Infertility: Encorafenib is a prescription drug. Male patients of childbearing potential should be informed that this drug may impair fertility, and its use must be in accordance with medical advice.
Lactation: It is recommended that women do not breastfeed during treatment with Encorafenib in combination with Binimetinib and for 2 weeks after the last dose.
1. If a dose of Encorafenib is missed by more than 12 hours, or vomiting occurs after administration, no additional dose is needed; the next scheduled dose should be taken as usual.
2. Risk of new primary malignant neoplasms: Patients are advised to contact their attending physician immediately if new skin lesions appear, existing skin lesions change, or other signs and symptoms of malignant neoplasms develop.
3. Bleeding risk: Patients are advised to contact a physician and seek emergency medical care immediately if signs and/or symptoms of abnormal bleeding occur (e.g., headache, dizziness, fatigue, bloody stool, hemoptysis, hematemesis).
FDA，2025.03
